[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiuli Zuo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100575421","efficacy-of-rifaximin-in-patients-with-small-intestinal-bacterial-overgrowth-presenting-with-abdominal-bloating-100575421",false,"NCT06772064","Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.","Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating: An Exploratory Study.","Healthy Group\n\nInclusion Criteria:\n\n1. Age between 18 and 70 years, both genders included.\n2. No special gastrointestinal discomfort such as bloating or abdominal pain, regular bowel movements, and normal stool characteristics.\n3. Negative hydrogen\u002Fmethane breath test.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of gastrointestinal malignancy or gastrointestinal surgery.\n3. Past diagnosis or suspicion of lactose intolerance.\n4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).\n5. Abnormalities in professional anxiety and depression symptom rating scales.\n6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.\n7. Those who cannot or are unwilling to sign an informed consent form.\n\nPatient Group:\n\nInclusion Criteria:\n\n1. Age between 18 and 70 years, both genders included.\n2. Chief complaints of abdominal bloating and\u002For distension; outpatients with abdominal bloating and\u002For distension more prominent than other symptoms.\n3. Positive hydrogen\u002Fmethane breath test.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of gastrointestinal malignancy or gastrointestinal surgery.\n3. Past diagnosis or suspicion of lactose intolerance.\n4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).\n5. Moderate to severe abnormalities in professional anxiety and depression symptom rating scales.\n6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.\n7. Those who cannot or are unwilling to sign an informed consent form.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},115,"ESTIMATED","INTERVENTIONAL",[25],"NA","Abdominal bloating is a common clinical symptom in the digestive system, with obscure origins and complex mechanisms. Its etiology can be attributed to organic diseases and various Functional Gastrointestinal Disorders (FGIDs). In recent years, the roles of Small Intestinal Bacterial Overgrowth (SIBO), Oral-Cecal Transit Time (OCTT), and gut microbiota dysbiosis in Functional Abdominal Bloating\u002FDistention (FAB\u002FD) have garnered increasing attention. Currently, there is a lack of diagnostic tests and effective treatment measures for patients with bloating. The hydrogen\u002Fmethane breath test is a safe, economical, and non-invasive examination recommended for diagnosing SIBO. Rifaximin, an antibiotic that acts exclusively in the intestines, has been widely validated for its efficacy in SIBO and in patients with SIBO co-occurring with Irritable Bowel Syndrome (IBS). However, research on the role of SIBO in the production of bloating symptoms and the extent to which rifaximin treatment of SIBO alleviates symptoms in clinical bloating patients is still lacking. This study aims to investigate the efficacy of rifaximin in patients with SIBO who primarily present with bloating. Exploring clinical treatment options for bloating provides a reference for its management. Furthermore, questionnaires on psychiatric symptoms and fecal microbiota analysis for patients with bloating-type SIBO can help clarify the etiology of bloating, offering a basis for the etiological treatment of bloating patients in the next steps.",[28],"SIBO",[28,30,31],"Abdominal bloating","Rifaximin","RECRUITING","2025-05-13",{"date":35,"type":36},"2025-05-16","ACTUAL",{"date":38,"type":36},"2025-04-15",{"date":40,"type":22},"2025-12-01",{"name":42,"class":43},"Xiuli Zuo","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100573817","observation-on-the-efficacy-of-radiofrequency-ablation-for-patients-with-moderate-to-severe-gastric-atrophy-with-enterosis-with-or-without-atrophy-of-intraepithelial-neoplasia-an-observational-study-100573817","NCT06751212","Observation on the Efficacy of Radiofrequency Ablation for Patients With Moderate to Severe Gastric Atrophy With Enterosis With or Without Atrophy of Intraepithelial Neoplasia: An Observational Study","Inclusion Criteria:\n\n* Age 18-70 years old, male or female.\n* Patients who had undergone gastroscopy within 3 months prior to inclusion, and whose histologic diagnosis of chronic gastritis was histologically atrophic enterocolitis graded at moderate-to-severe with or without low-grade intraepithelial neoplasia.\n* Patients who had undergone gastroscopy within 3 months prior to inclusion, and whose OLGA (atrophic grading and staging criteria for chronic gastritis) or OLGIM (enteric grading and staging criteria for chronic gastritis) staging criteria had reached moderately severe.\n* Helicobacter pylori negative.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Previous history of malignant tumors of the digestive tract or history of gastrointestinal surgery.\n* Malignant tumors of other organs, coagulation disorders, cardiopulmonary insufficiency, hepatic and renal insufficiency, etc.\n* Those who are unable or unwilling to sign the informed consent form.",{"count":52,"type":22},62,"OBSERVATIONAL","The aim of this observational study was to understand the effect of radiofrequency ablation on subjects with moderate to severe gastric atrophy with enterocolitis with or without low-grade intraepithelial neoplasia who underwent radiofrequency ablation. The main question it aims to answer is:\n\nDoes radiofrequency ablation therapy reduce gastric mucosal atrophy and enterosis in subjects with moderate to severe gastric atrophy with enterosis with or without low-grade intraepithelial neoplasia?",[56],"Atrophic Gastritis","NOT_YET_RECRUITING","2024-12-26",{"date":60,"type":36},"2024-12-27",{"date":62,"type":22},"2024-12-31",{"date":64,"type":22},"2028-03-30",{"name":42,"class":43},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":72,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":44},"100572265","efficacy-of-a-14-day-bismuth-containing-quadruple-therapy-guided-by-drug-susceptibility-testing-in-patients-with-extremely-refractory-helicobacter-pylori-infection-an-exploratory-study-100572265","NCT06731023","Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study","Inclusion Criteria:\n\n1. Patients aged 18-65.\n2. Patients with H.pylori infection (Positive for rapid urease test or 13C urea breath test).\n3. Received at least two previous standard treatment protocols for Helicobacter pylori, and the application regimens included at least three low-resistance antibiotics.\n\nExclusion Criteria:\n\n1. Patients with serious underlying diseases, such as liver insufficiency, renal insufficiency, immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%.\n2. Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial.\n3. Patients with active gastrointestinal bleeding.\n4. Patients with a history of upper gastrointestinal surgery.\n5. Patients allergic to treatment drugs.\n6. Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks\n7. Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse\n8. Patients who are unwilling or incapable to provide informed consents.",{"count":73,"type":22},30,"Helicobacter pylori (H. pylori) infection, a prevalent global infectious disease, is a significant contributor to gastric cancer and other morbidities, imposing a substantial disease burden. With the rise in antibiotic resistance, the eradication of H. pylori is encountering formidable challenges. A subset of individuals, despite undergoing multiple treatment regimens, remain unable to successfully eradicate the infection. The persistence of infection in these cases could be attributed to either the limitations of detection methods leading to false positives or to the infection by superbugs that are highly resistant to antibiotics. This study is designed to ascertain whether these patients are infected with superbugs by employing various diagnostic techniques. Additionally, it aims to assess the antibiotic resistance profiles of strains associated with extremely refractory H. pylori infections through drug susceptibility testing. Based on the identified sensitivities, the study seeks to tailor treatment protocols with bismuth-containing quadruple therapy (Containing two kinds of antibiotics: sensitive antibiotic, rifabutin or high-dose metronidazole), to explore novel therapeutic strategies for patients with highly resistant H. pylori infections.",[76],"HELICOBACTER PYLORI INFECTIONS",[78,79,80],"Helicobacter pylori","Bismuth-Containing Quadruple Therapy","Drug Susceptibility Testing","2024-12-16",{"date":83,"type":36},"2024-12-19",{"date":85,"type":22},"2025-01-01",{"date":87,"type":22},"2026-12-31",{"name":42,"class":43},""]